Mitralign Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 43

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Mitralign General Information

Description

Developer of a direct trans-catheter annuloplasty system designed to treat both tricuspid and mitral regurgitation. The company's system designs therapies for the reduction of functional mitral regurgitation, which is a global life-threatening cardiac condition, enabling healthcare providers to treat symptomatic functional mitral regurgitation for annular reduction through tissue-plication.

Contact Information

Website
www.mitralign.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3 Highwood Drive
  • Suite 200 East
  • Tewksbury, MA 01876
  • United States
+1 (978)
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Acquirer
Edwards Lifesciences
Corporate Office
  • 3 Highwood Drive
  • Suite 200 East
  • Tewksbury, MA 01876
  • United States
+1 (978)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mitralign Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 12-Mar-2019 Completed Profitable
11. Later Stage VC (Series F) 20-Feb-2018 Completed Profitable
10. Later Stage VC (Series E) 16-May-2016 Completed Profitable
9. Debt - General 22-Apr-2016 Completed Profitable
8. Later Stage VC (Series E) 19-Jun-2014 Completed Profitable
7. Later Stage VC 26-Oct-2012 Completed Profitable
6. Debt - General 11-Sep-2012 Completed Profitable
5. Later Stage VC (Series D) 16-May-2012 Completed Profitable
4. Debt - General 01-Jul-2010 $42.5M Completed Profitable
3. Later Stage VC (Series C) 10-Dec-2007 $24.1M $42.5M Completed Profitable
To view Mitralign’s complete valuation and funding history, request access »

Mitralign Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series F
Junior Convertible
Series E
Series D2
Series D1
Series C
Series B
Series A2 47,619 $0.001000 $105 $105 1x $91.72 0.13%
Series A1 13,152 $0.001000 $105 $105 1x $91.72 0.04%
To view Mitralign’s complete cap table history, request access »

Mitralign Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a direct trans-catheter annuloplasty system designed to treat both tricuspid and mitral regurgitation. The
Surgical Devices
Tewksbury, MA
43 As of 2014

Irvine, CA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mitralign Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ClearFlow Venture Capital-Backed Irvine, CA
Polares Medical Venture Capital-Backed Palo Alto, CA
Micro Interventional Devices Venture Capital-Backed Newtown, PA
Valcare Venture Capital-Backed Herzliya, Israel
JenaValve Technology Pending Transaction (M&A) Irvine, CA
You’re viewing 5 of 12 competitors. Get the full list »

Mitralign Patents

  • 54

    Total Documents Applications and Grants

  • Total Patents Families

  • 20

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Mitralign Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160256269-A1 Devices for treating paravalvular leakage and methods use thereof Inactive 05-Mar-2015
EP-3013250-A1 Percutaneous valve repair by reshaping and resizing right ventricle Inactive 25-Jun-2013
EP-3013250-A4 Percutaneous valve repair by reshaping and resizing right ventricle Inactive 25-Jun-2013
EP-2961351-A4 Devices and methods for percutaneous tricuspid valve repair Active 26-Feb-2013
EP-2961351-B1 Devices for percutaneous tricuspid valve repair Active 26-Feb-2013 A61B17/0401
To view Mitralign’s complete patent history, request access »

Mitralign Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mitralign Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
ABN AMRO Bank Corporation Minority
DHC Systems Corporation Minority
DNV Capital Venture Capital Minority
Delian Capital Venture Capital Minority
Delong Capital Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Mitralign FAQs

  • When was Mitralign founded?

    Mitralign was founded in 2003.

  • Who is the founder of Mitralign?

    Rick Geoffrion is the founder of Mitralign.

  • Where is Mitralign headquartered?

    Mitralign is headquartered in Tewksbury, MA.

  • What is the size of Mitralign?

    Mitralign has 43 total employees.

  • What industry is Mitralign in?

    Mitralign’s primary industry is Surgical Devices.

  • Is Mitralign a private or public company?

    Mitralign is a Private company.

  • What is Mitralign’s current revenue?

    The current revenue for Mitralign is .

  • How much funding has Mitralign raised over time?

    Mitralign has raised $146M.

  • Who are Mitralign’s investors?

    ABN AMRO Bank, DHC Systems, DNV Capital, Delian Capital, and Delong Capital are 5 of 17 investors who have invested in Mitralign.

  • Who are Mitralign’s competitors?

    ClearFlow, Polares Medical, Micro Interventional Devices, Valcare, and JenaValve Technology are some of the 12 competitors of Mitralign.

  • When was Mitralign acquired?

    Mitralign was acquired on 12-Mar-2019.

  • Who acquired Mitralign?

    Mitralign was acquired by Edwards Lifesciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »